- Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial
[作者：Biere, SSAY; Henegouwen, MIV; Maas, KW; Bonavina, L; Rosman, C; Garcia, JR; Gisbertz, SS; Klinkenbijl, JHG; Hollmann, MW; de Lange, ESM; Bonjer, HJ; van der Peet, DL; Cuesta, MA,期刊：Lancet, 页码：1887-1892 , 文章类型： Article，,卷期：2012年379-9829]
- Background Surgical resection is regarded as the only curative option for resectable oesophageal cancer, but pulmonary complications occurring in more than half of patients after open oesophagectomy are a great concern. ...
- Tackling NCDs: a different approach is needed
[作者：De Maeseneer, J; Roberts, RG; Demarzo, M; Heath, I; Sewankambo, N; Kidd, MR; van Weel, C; Egilman, D; Boelen, C; Willems, S,期刊：Lancet, 页码：1860-1861 , 文章类型： Editorial Material，,卷期：2012年379-9829]
-
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
[作者：Falchook, GS; Long, GV; Kurzrock, R; Kim, KB; Arkenau, TH; Brown, MP; Hamid, O; Infante, JR; Millward, M; Pavlick, AC; O'Day, SJ; Blackman, SC; Curtis, CM; Lebowitz, P; Ma, B; Ouellet, D; Kefford, RF,期刊：Lancet, 页码：1893-1901 , 文章类型： Article，,卷期：2012年379-9829]
- Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours,...
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
[作者：van der Graaf, WTA; Blay, JY; Chawla, SP; Kim, DW; Binh, BN; Casali, PG; Schoffski, P; Aglietta, M; Staddon, AP; Beppu, Y; Le Cesne, A; Gelderblom, H; Judson, IR; Araki, N; Ouali, M; Marreaud, S; Hodge, R; Dewji, MR; Coens, C; Demetri, GD; Fletcher, CD; Tos, APD; Hohenberger, P,期刊：Lancet, 页码：1879-1886 , 文章类型： Article，,卷期：2012年379-9829]
- Background Pazopanib, a multitargeted tyrosine kinase inhibitor, has single-agent activity in patients with advanced non-adipocytic soft-tissue sarcoma. We investigated the effect of pazopanib on progression-free surviva...
|